Literature DB >> 7535334

Mutational analysis and an alternatively spliced product of B7 defines its CD28/CTLA4-binding site on immunoglobulin C-like domain.

Y Guo1, Y Wu, M Zhao, X P Kong, Y Liu.   

Abstract

Costimulatory molecules B7 and B7-2 interact with T cell surface receptors CD28/CTLA4 and deliver a costimulatory signal essential for T cell growth. However, the structure basis of this interaction is not known. B7 and B7-2 are members of immunoglobulin (Ig) superfamily and their extracellular portion consists of an IgV- and IgC-like domain. Here we report that a naturally occurring, alternatively spliced form of B7 reveals that exon 3-encoded IgC domain is essential for CD28/CTLA4 binding. Mutational analysis of B7 demonstrates a critical role of several amino acids around loops between strands B and C and D and E, for binding CTLA4/CD28. These amino acids are clustered to form a single binding site centered at 201Y. A comparison of the effects of mutations on the binding of CD28 and CTLA4 reveals that CD28 and CTLA4 binds to the same site on B7. These results have important implications on the role of CTLA4 and CD28 in T cell costimulation. The structure of the CD28/CTLA4-binding site also provides valuable information for immune intervention targeted at the B7/B7-2-CD28/CTLA4 interactions.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7535334      PMCID: PMC2191977          DOI: 10.1084/jem.181.4.1345

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  45 in total

1.  T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo.

Authors:  L A Turka; P S Linsley; H Lin; W Brady; J M Leiden; R Q Wei; M L Gibson; X G Zheng; S Myrdal; D Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-15       Impact factor: 11.205

Review 2.  Costimulation of T-cell growth.

Authors:  Y Liu; P S Linsley
Journal:  Curr Opin Immunol       Date:  1992-06       Impact factor: 7.486

3.  CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones.

Authors:  F A Harding; J G McArthur; J A Gross; D H Raulet; J P Allison
Journal:  Nature       Date:  1992-04-16       Impact factor: 49.962

4.  Co-stimulation of murine CD4 T cell growth: cooperation between B7 and heat-stable antigen.

Authors:  Y Liu; B Jones; W Brady; C A Janeway; P S Linsley; P S Linley
Journal:  Eur J Immunol       Date:  1992-11       Impact factor: 5.532

5.  Expression and function of the murine B7 antigen, the major costimulatory molecule expressed by peritoneal exudate cells.

Authors:  Z Razi-Wolf; G J Freeman; F Galvin; B Benacerraf; L Nadler; H Reiser
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-01       Impact factor: 11.205

6.  Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg.

Authors:  D J Lenschow; Y Zeng; J R Thistlethwaite; A Montag; W Brady; M G Gibson; P S Linsley; J A Bluestone
Journal:  Science       Date:  1992-08-07       Impact factor: 47.728

7.  In vitro induction of T cell anergy by blocking B7 and early T cell costimulatory molecule ETC-1/B7-2.

Authors:  C Chen; N Nabavi
Journal:  Immunity       Date:  1994-05       Impact factor: 31.745

8.  Structure, expression, and T cell costimulatory activity of the murine homologue of the human B lymphocyte activation antigen B7.

Authors:  G J Freeman; G S Gray; C D Gimmi; D B Lombard; L J Zhou; M White; J D Fingeroth; J G Gribben; L M Nadler
Journal:  J Exp Med       Date:  1991-09-01       Impact factor: 14.307

9.  Heat-stable antigen is a costimulatory molecule for CD4 T cell growth.

Authors:  Y Liu; B Jones; A Aruffo; K M Sullivan; P S Linsley; C A Janeway
Journal:  J Exp Med       Date:  1992-02-01       Impact factor: 14.307

10.  Activation-induced death by apoptosis in CD4+ T cells from human immunodeficiency virus-infected asymptomatic individuals.

Authors:  H Groux; G Torpier; D Monté; Y Mouton; A Capron; J C Ameisen
Journal:  J Exp Med       Date:  1992-02-01       Impact factor: 14.307

View more
  8 in total

1.  Identification of a costimulatory molecule rapidly induced by CD40L as CD44H.

Authors:  Y Guo; Y Wu; S Shinde; M S Sy; A Aruffo; Y Liu
Journal:  J Exp Med       Date:  1996-09-01       Impact factor: 14.307

2.  B7-CTLA4 interaction enhances both production of antitumor cytotoxic T lymphocytes and resistance to tumor challenge.

Authors:  P Zheng; Y Wu; Y Guo; C Lee; Y Liu
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-26       Impact factor: 11.205

Review 3.  Targeted Therapy of B7 Family Checkpoints as an Innovative Approach to Overcome Cancer Therapy Resistance: A Review from Chemotherapy to Immunotherapy.

Authors:  Bita Amir Taghavi; Nazila Alizadeh; Hossein Saeedi; Noora Karim Ahangar; Afshin Derakhshani; Khalil Hajiasgharzadeh; Nicola Silvestris; Behzad Baradaran; Oronzo Brunetti
Journal:  Molecules       Date:  2022-05-31       Impact factor: 4.927

4.  CTLA-4-B7 interaction is sufficient to costimulate T cell clonal expansion.

Authors:  Y Wu; Y Guo; A Huang; P Zheng; Y Liu
Journal:  J Exp Med       Date:  1997-04-07       Impact factor: 14.307

5.  Cytotoxic T lymphocytes to an unmutated tumor rejection antigen P1A: normal development but restrained effector function in vivo.

Authors:  S Sarma; Y Guo; Y Guilloux; C Lee; X F Bai; Y Liu
Journal:  J Exp Med       Date:  1999-03-01       Impact factor: 14.307

Review 6.  The B7 family of immune-regulatory ligands.

Authors:  Mary Collins; Vincent Ling; Beatriz M Carreno
Journal:  Genome Biol       Date:  2005-05-31       Impact factor: 13.583

7.  Identification of residues in the V domain of CD80 (B7-1) implicated in functional interactions with CD28 and CTLA4.

Authors:  C A Fargeas; A Truneh; M Reddy; M Hurle; R Sweet; R P Sékaly
Journal:  J Exp Med       Date:  1995-09-01       Impact factor: 14.307

8.  B7DC/PDL2 promotes tumor immunity by a PD-1-independent mechanism.

Authors:  Xingluo Liu; Jian Xin Gao; Jing Wen; Lijie Yin; Ou Li; Tao Zuo; Thomas F Gajewski; Yang-Xin Fu; Pan Zheng; Yang Liu
Journal:  J Exp Med       Date:  2003-06-16       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.